Lv1
30 积分 2024-10-24 加入
ADC for SCLC Clears Phase I
1个月前
已完结
39P: Real-world efficacy and safety of anlotinib in NSCLC previously treated with immune checkpoint inhibitors
6个月前
已完结
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
10个月前
已完结
皖公网安备34019202002308
